Page last updated: 2024-08-21

selenocystine and ER-Negative PR-Negative HER2-Negative Breast Cancer

selenocystine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hao, J; Li, X; Liu, W; Long, M; Qiu, W; Su, H; Tang, Y; Wu, J	1

Other Studies

1 other study(ies) available for selenocystine and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation. In vitro cellular & developmental biology. Animal, 2015, Volume: 51, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystine; Dose-Response Relationship, Drug; Female; Humans; Organoselenium Compounds; S Phase Cell Cycle Checkpoints; Triple Negative Breast Neoplasms	2015

Article

Year

Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation.

In vitro cellular & developmental biology. Animal, 2015, Volume: 51, Issue:10

Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystine; Dose-Response Relationship, Drug; Female; Humans; Organoselenium Compounds; S Phase Cell Cycle Checkpoints; Triple Negative Breast Neoplasms

2015